Warning: Unknown: Unable to allocate memory for pool. in Unknown on line 0 Access to Information Requests Completed - January 2014 - Health Canada
Health Canada
Symbol of the Government of Canada

Common menu bar links

About Health Canada

Access to Information Requests Completed - January 2014

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

AER
Adverse Reaction Report (Adverse Event)
DIN
Drug Identification Number
NPN
Natural Product Number
 
For the month of January 2014
Request # Summary of Requests Status of Completed Request Number of Pages Disclosed
A-2010-00504 Information relative to Health Canada's human health risk assessment involving carotenoids in foods. Disclosed in part 163
A-2010-00523 Documents related to an infant formula company with the brand name Parent's Choice. (Jan 1, 2007 to Jul 28, 2010). Disclosed in part 39
A-2010-01518 Documents related to the topic of Antibiotics and Livestock in preparation for or related to appearance by Paul Glover, Deputy Minister, Health Products and Foods Branch and Daniel Chaput, Director General Veterinary Drugs Directorate; before the Standing Committee on Health, Meeting No.55 March 10, 2011. Disclosed in part 802
A-2011-00047 Information regarding Janumet by Merck Canada Inc. Disclosed in part 730
A-2011-01358 Information regarding Duragesic, DINs 01937383, 01937391, 01937405, 01937413, 02334186 by Janssen Inc. Disclosed in part 98
A-2011-01361 Information regarding Sinemet by Merck Canada Inc. Disclosed in part 271
A-2011-01439 Information regarding Trophic Mega Cordyceps Cs-4, NPN 80005953 by Trophic Canada. Disclosed in part 119
A-2011-01556 Information regarding Stelara, DIN 02320673 by Janssen Inc. Disclosed in part 1,592
A-2011-01705 Information regarding IRESSA, DIN 02248676 by AstraZeneca Canada Inc. Disclosed in part 942
A-2012-00007 Information regarding the medical device TALENT AAA STENT GRAFT BIF ABD AORTIC STENT W/XCELERANT HYDRO DELIVERY SYS, License number 77830. Disclosed in part 237
A-2012-00114 Information regarding Rephresh Pro-B, NPN 80012146 by Lil' Drug Store Products Inc. Disclosed in part 874
A-2012-00122 Information regarding Crest Pro-Health Clinical Plaque Control, NPN 80029123 by Procter and Gamble Inc. Disclosed in part 61
A-2012-00123 Information regarding Crest Shield Protect; Crest Pro-Health Clinical Gum Protection, NPN 80012433 by Procter and Gamble Inc. Disclosed in part 169
A-2012-00166 Information regarding Nutrilite Vitamin C Plus (Extended Release), NPN 80030807 by Amway Canada Corporation. Disclosed in part 78
A-2012-00448 Information regarding NPN 80030101 by Organika Health Products Inc. Disclosed in part 62
A-2012-00454 Information regarding the medical device HIGH FREQUENCY OSCILLATORY VENTILATOR MODEL 3100B, License number 27517 by CAREFUSION. Disclosed in part 216
A-2012-00700 AERs for CIPRALEX (Escitalopram). (Jan 1, 2005 to Aug 8, 2012). Disclosed in part 122
A-2012-00702 AERs for ZOLOFT (sertraline hydrochloride). (Jan 1, 2005 to Aug 8, 2012). Disclosed in part 2
A-2012-00738 Information regarding Rasilez by NOVARTIS PHARMACEUTICALS CANADA INC. Disclosed in part 1,985
A-2012-00800 Information regarding Accutane Roche (isotretinoin) by Hoffman-La Roche Limited. Disclosed in part 103
A-2012-00873 Information regarding MAXIDOL Liquid Gels (naproxen sodium), DIN 02372991 by BAYER INC CONSUMER CARE. Disclosed in part 129
A-2012-00880 Documents between Daniel Tessier, Auditing Manager, Special Reviews, and Kevin Stewart, Manager, Accountability, regarding a case of health-care fraud amounting to approximately $504K. (Jun 1, 2011 to Aug 22, 2012). Disclosed in part 55
A-2013-00029 Documents related to Kraft and its use of tartrazine. (Jun 1, 2011 to Apr 9, 2013). Disclosed in part 83
A-2013-00462 Documents related to high powered magnets and high powered magnet sets. (Jan 1, 2009 to Jul 26, 2013). Disclosed in part 627
A-2013-00639 Documents showing the names of individuals or corporations who met the Health Canada minister or Health Canada officials to discuss BOTOX or BOTOX JUVERDERM. (Jan 1, 2013 to Sep 9, 2013). Disclosed in part 6
A-2013-00654 All briefing notes regarding Apotex's Alysena 28. (Jan 1, 2013 to May 21, 2013). All disclosed 19
A-2013-00668 All briefing materials prepared for the Minister of Health related to Canada Health Accord. (Jul 1, 2013 to Sep 13, 2013). Disclosed in part 52
A-2013-00669 All organizational charts from the Veterinary Drugs Directorate. (Sep 1, 2010 to Sep 13, 2013). Disclosed in part 25
A-2013-00672 All contracts and staffing actions related to the use of temporary help, contractual, consultant and all non-indeterminate staffing within the Veterinary Drugs Directorate. (Apr 1, 2012 to Sep 13 2013). Disclosed in part 143
A-2013-00674 Documents relating to all staff directorate meetings within the Veterinary Drugs Directorate. (Sep 1, 2011 to Sep 1, 2013). Disclosed in part 85
A-2013-00685 All contracts processed in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Task and Solutions Professional Services and for Task-Based Informatics Professional Services during the months of April, May and June 2013. Disclosed in part 187
A-2013-00690 AERs for the following products/report numbers: Cipraelx (000491490, 000494140, 000496756, 000499006, 000499703, 000502791, 000507336, 000508853), Celexa (000503586), Fluanxol (000511545, 000512786), Clopixol (000493647), Ebixa (000498101, 000494640), Treanda (000506694). Disclosed in part 39
A-2013-00730 Documents relating to the meetings of the Organization for Economic Co-operation and Development (OECD) Pesticide Program's Working Group on Pesticides. (Sep 26, 2008 to Sep 25, 2013). All exempted 0
A-2013-00731 Documents relating to procedures established regarding the exchange with the Organization for Economic Co-operation and Development (OECD) member countries of information respecting active ingredients of pest control products that are prohibited by a member country of the OECD for environmental or health reasons. All disclosed 11
A-2013-00732 Records documenting any policies, guidelines, practices or procedures established or followed by the Minister of Health and/or Pest Management Regulatory Agency in relation to section 22 of the Pest Control Products Act or in relation to discontinuance of a registered pest control product. All disclosed 31
A-2013-00803 Documents on the Medical Marihuana Access Program regarding the following:
- The number of inspectors to investigate misuse or fraud
- The number of inspections
- The number of times a licensed producer violated their licence
- The number of dispensaries
Disclosed in part 15
A-2013-00820 Most recent version of the Memorandum of Understanding between Health Canada (HC) and Industry Canada (IC) which assigns to HC the role of principal advisor to IC regarding radiation hazards to human health. All disclosed 7
A-2013-00829 Documents relating to the decision to assume control of the Canadian Food Inspection Agency. (Jan 1, 2013 to Oct 11, 2013). Disclosed in part 10
A-2013-00865 Question Period Cards and materials for the Minister or Parliamentary Secretaries. (Oct 16, 2013 to Oct 21, 2013). Disclosed in part 19
A-2013-00883 AERs for the following products/report numbers: Prozac (000513964, 000535213), Strattera (000517919), Cialis (000531431), Gemzar (000518747) Disclosed in part 15
A-2013-00884 AERs for Humalog. Report numbers: 000513090, 000525226, 000527297, 000529050, 000530568, 000547534 and 000529224. Disclosed in part 15
A-2013-00886 AERs for Cymbalta. Report numbers: 000529669, 000530220, 000530328, 000531205, 000531978, 000532246, 000532624, 000533209, 000533872, 000537638 and 000537601. Disclosed in part 18
A-2013-00889 Information regarding Organika Health Products Inc. Hi Potency Salmon Collagen Capsules; Coastal Mountain Naturals Tm Salmon Collagen Capsules; Herbal Whisper Salmon Collagen 500 Mg Capsules; Herbs Of Gold Hydrolyzed Salmon Collagen; Organika Professional Line Hi Potency Salmon Collagen Capsules; Salmon Collagen (Vitahealth) Capsules; Vitahealth Salmon Collagen Capsules; Vitapath Salmon Collagen Capsules; Westcoast Naturals Hi Potency Salmon Collagen Capsules, NPN 80045589 by Organika Health Products Inc. Disclosed in part 80
A-2013-00897 All correspondence in the Minister's office regarding safe injection sites. (Sep 1 2013 to Oct 30, 2013). Disclosed in part 79
A-2013-00923 Documents regarding the exact number of Personal Production Licence and Designated Production Licence under the current Marihuana Medical Access Regulations. All disclosed 1
A-2013-00924 AERs for Humira. Report numbers: 000521418, 000522676, 000529246 and 000536701. Disclosed in part 17
A-2013-00927 AER for Kaletra. Report number: 000533528. Disclosed in part 3
A-2013-00930 List of all correspondence with the Minister regarding the Study to Assess Long Term Opioid Maintenance Effectiveness (SALOME). (Jan 1, 2013, to Nov 15, 2013). All disclosed 1
A-2013-00953 AERs for Acetaminophen. (Jan 1, 2005 to Nov 7, 2013). Disclosed in part 2,164
A-2013-00966 Cross-Canada Survey of Radon Concentrations in Homes (2012). List of all homes that were tested for radon above 200 Bq/m3. All disclosed 2,000
A-2013-00968 Cross-Canada Survey of Radon Concentrations in Homes (2012). All electronic digital form databases and/or data sets generated and/or created with the data from this survey. All disclosed 2,150
A-2013-00988 Documentations regarding the processes of being exempted from Part II, section 13 of the Tobacco Act. No records exist 0
A-2013-00990 Study carried out jointly by Health Canada and the National Research Council on Mitigation Strategies to prevent the infiltration of pollutants from attached garages into the living spaces of residential homes. Disclosed in part 38
A-2013-00999 Documents related to statistics of miscarriages by women in Canada and miscarriages caused by pharmaceuticals or natural health products. (Jan 1, 1999 to Nov 20, 2013). No records exist 0
A-2013-01041 The overall number of production sites and licenses to produce cannabis (marihuana) that have been issued under the Marihuana Medical Access Program to recipients within the District of Mission, British Columbia. All disclosed 1
A-2013-01044 AER for Eloxatin. Report number: 000515045. Disclosed in part 6
A-2013-01047 The most recent report about the normal allowable levels of different chemicals and metals including Strontium, Barium, Aluminum, Mercury, Lithium, Cadmium, Cesium, arsenic, mercury, lead and selenium in the air, water, and soil in Canada. All disclosed 22
A-2013-01062 AERs. Report numbers: 000512657, 000518379 and 000529681. Disclosed in part 15
A-2013-01102 List of briefing notes and memoranda created or transmitted to Minister Rona Ambrose. (Nov 1, 2013 to Dec 9, 2013). Disclosed in part 21
A-2013-01117 Various statistical information regarding prescriptions for medical marihuana. (Jan 1, 2007 to Dec 16, 2013). All disclosed 4
A-2013-01119 Reports and/or advice provided to Natural Resources Canada regarding the Melancthon Wind energy project Phase I, and Amaranth II also known as Melancthon II Grey Wind Project proposed by Canadian Hydro Developers, Inc. and TransAlta Corporation. (Jan 1, 2004 to Dec 31, 2011). All disclosed 15
A-2013-01124 Job description and the classification rationale for position HCF103PS01, Manager Finance. All disclosed 6
A-2013-01141 Affiliate Agreements of Canada Health Infoway with Health Level Seven (HL7) International related licenses. Licenses which accompany Licensed International and pan-Canadian HL 7 Standards for: Individual, and Organizational, Infoway Standards Collaborative memberships. (Jan 1, 1995 to Dec 23, 2013). No records exist 0
A-2013-01145 Templates, guidelines, standards, policies and other guidance used in preparing memoranda's or briefing notes for the minister. All disclosed 22
A-2013-01146 AERs. Report numbers: 000459968 and 000459969. Disclosed in part 2
A-2013-01154 Postal codes of the 2,000 dwellings selected for the federal government's study on the effects of wind turbines. No records exist 0
A-2013-01168 Copy of the March 16, 2012, issues report regarding a Statistics Canada's questionnaire on wind turbine noise. No records exist 0
A-2013-01169 Documents related to the Statistics Canada's questionnaire on wind turbine noise from the Minister's Office staff to the bureaucracy. No records exist 0
A-2013-01185 AER for PRADAXA. Report number: 000500659. Disclosed in part 1
A-2013-01202 AER for SPIRIVA. Report number: 000166779. Disclosed in part 1
A-2013-01203 AER for SPIRIVA. Report number: 000158180. Disclosed in part 1
A-2013-01204 AER for SPIRIVA. Report number: 000167471. Disclosed in part 1
A-2013-01205 AER for SPIRIVA. Report number: 000160881. Disclosed in part 1
A-2013-01210 AER for TRAJENTA. Report number: 000530588. Disclosed in part 1
A-2013-01211 AER for TRAJENTA. Report number: 000535874. Disclosed in part 1